Rapastinel

Allergan plc (NYSE: AGN) was in for a disappointment with its investigational depression drug candidate Rapastinel, one day after Johnson & Johnson (NYSE: JNJ) secured FDA approval for its treatment-resistant depression drug esketamine. The Analysts Wells Fargo Securities analyst David Maris...

Allergan plc Ordinary Shares (NYSE: AGN) have seen heavy selling pressure throughout parts of 2017, but some analysts are encouraging investors to take advantage of the weakness. The Analyst Morgan Stanley's David Risinger upgraded Allergan's stock rating from Equal-weight to Overweight...

Analysts at Credit Suisse presented the bull and bear cases for Allergan plc Ordinary Shares (NYSE: AGN) in a research note on Monday. The analysts see the stock trading at $329 as a "base case" scenario, $391 under a "bull case" scenario and $200 under a "bear case" scenario. The Bull Case Under...